中國核能科技(00611.HK)委任葉晗為公司祕書,授權代表及法律程序代理人
格隆匯1月23日丨中國核能科技(00611.HK)宣佈,因陳耀榮希望投入更多時間於其他業務發展,彼已提呈辭任公司的公司祕書("公司祕書"),且不再擔任聯交所證券上市規則第3.05條所指的公司授權代表("授權代表"),以及上市規則第19.05(2)條和公司條例(香港法例第622章)第16部所規定在香港代表公司接收法律程序文件及通知的公司授權代表("法律程序代理人"),均自2025年1月23日起生效。
進一步宣佈,葉晗已獲委任為公司的公司祕書,授權代表及法律程序代理人,自2025年1月23日起生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.